EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Patient-Derived 3D-Bioprinted Models of Pancreatic Cancer: Toward Personalized Therapy and Overcoming Tumor Microenvironment Challenges

Daniella Vaskovich-Koubi, Marina Green Buzhor, Anne Krinsky, Yair Roth, Koren Salomon, Ron Kleiner, Rina Sevostianov, Ohad Hasin, Rami Khoury, Ronit Satchi-Fainaro

Advanced Drug Delivery Reviews · 2025-10 · 225 · 115670

DOI: 10.1016/j.addr.2025.115670 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2025-10. Verfasst von Daniella Vaskovich-Koubi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Gray Faculty of Medical and Health Sciences, Gray School of Medical Sciences, Tel Aviv University, Tel Avi…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Pancreatic Neoplasms, Precision Medicine, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 202 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Research Council (ERC), European Research Council (ERC) -PoC, The European Innovation Council (EIC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and treatment-resistant solid tumors, mainly due to its complex tumor microenvironment (TME). Characterized by dense desmoplastic stroma, immune suppression, and metabolic rewiring, the TME impairs drug delivery and eventually leads to therapeutic failure. Conventional models, such as two-dimensional (2D) cultures and mouse models, fail to recapitulate the cellular and mechanical intricacies of PDAC, limiting their translational relevance. Three-dimensional (3D) models have emerged as promising tools to better simulate tumor biology. Among them, 3D-bioprinting techniques enable the precise spatial organization of cancer, stromal, and immune cells within tailored bioinks, supporting physiologically relevant architectures and dynamic microenvironmental interactions. These platforms allow controlled incorporation of extracellular matrix components, tunable stiffness, and perfusable vasculature, improving model fidelity and enabling real-time assessment of drug penetration, immune infiltration, and therapy resistance. This review provides a comprehensive overview of current 3D PDAC modeling strategies, emphasizing patient-derived 3D-bioprinted models. We explore the key roles of bioink composition, extracellular matrix (ECM) stiffness, perfusion capacity, and immuno-compatibility in shaping the fidelity and utility of these models. Furthermore, we compare the structural complexity, scalability, drug-screening capabilities, and applicability for personalized medicine of different 3D models. By highlighting advances in vascularization, immune co-culture, and biofabrication technologies, we underscore the emerging value of 3D-bioprinting as a transformative platform for preclinical PDAC research. Ultimately, 3D-bioprinting is an important step forward in bridging the gap between preclinical studies and clinical implementation, as it opens the door to more accurate, personalized, and efficient therapeutic approaches for PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentPancreatic NeoplasmsPrecision MedicineCarcinoma, Pancreatic DuctalPrinting, Three-DimensionalBioprintingHumansAnimals

Stichwörter der Autor:innen

3D-bioprintingBioinksDrug screeningPancreatic ductal adenocarcinoma (PDAC)Patient-derived modelsPersonalized therapyTarget discoveryTumor microenvironment (TME)

Autor:innen und Institutionen

  • Department of Physiology and Pharmacology, Gray Faculty of Medical and Health Sciences, Gray School of Medical Sciences, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Department of Physiology and Pharmacology, Gray Faculty of Medical and Health Sciences, Gray School of Medical Sciences, Tel Aviv University, Tel Aviv 6997801, Israel; Tel Aviv University Center for Nanoscience and Nano…

Förderung

  • European Research Council (ERC)
  • European Research Council (ERC) -PoC
  • The European Innovation Council (EIC)
  • Israel Cancer Research Fund
  • European Innovation Council
  • Caixabank SA
  • Israel Science Foundation

Zitieren

APA

Vaskovich-Koubi, D., Green Buzhor, M., Krinsky, A., Roth, Y., Salomon, K., Kleiner, R., Sevostianov, R., Hasin, O., Khoury, R., & Satchi-Fainaro, R. (2025). Patient-Derived 3D-Bioprinted Models of Pancreatic Cancer: Toward Personalized Therapy and Overcoming Tumor Microenvironment Challenges. Advanced Drug Delivery Reviews, 225, 115670. https://doi.org/10.1016/j.addr.2025.115670

Vancouver

Vaskovich-Koubi D, Green Buzhor M, Krinsky A, Roth Y, Salomon K, Kleiner R, et al. Patient-Derived 3D-Bioprinted Models of Pancreatic Cancer: Toward Personalized Therapy and Overcoming Tumor Microenvironment Challenges. Advanced Drug Delivery Reviews. 2025;225:115670. doi:10.1016/j.addr.2025.115670

BibTeX
@article{VaskovichKoubi2025,
  author = {Vaskovich-Koubi, Daniella and Green Buzhor, Marina and Krinsky, Anne and Roth, Yair and Salomon, Koren and Kleiner, Ron and Sevostianov, Rina and Hasin, Ohad and Khoury, Rami and Satchi-Fainaro, Ronit},
  title = {Patient-Derived 3D-Bioprinted Models of Pancreatic Cancer: Toward Personalized Therapy and Overcoming Tumor Microenvironment Challenges},
  journal = {Advanced Drug Delivery Reviews},
  year = {2025},
  volume = {225},
  pages = {115670},
  doi = {10.1016/j.addr.2025.115670}
}
Kostenlos starten →